Congestive heart failure: Difference between revisions

Jump to navigation Jump to search
 
(11 intermediate revisions by 4 users not shown)
Line 8: Line 8:
{{Congestive heart failure}}
{{Congestive heart failure}}


{{CMG}}; {{AE}} {{LG}}, {{MehdiP}} {{HK}}
{{CMG}}; {{AE}} {{LG}}, {{Mitra}} {{MehdiP}} {{HK}} [[User:Edzelco|Edzel Lorraine Co, D.M.D., M.D.]] [Mailto:efco@alum.up.edu.ph]


{{SK}} CHF; pump failure; left heart failure; chronic heart failure; acute heart failure; LV dysfunction; LV failure; impaired filling; reduced cardiac output; HFpEF; HFrEF; heart failure preserved ejection fraction; heart failure reduced ejection fraction; decompensated heart failure; acute decompensated heart failure; ADHF
{{SK}} CHF; pump failure; left heart failure; chronic heart failure; acute heart failure; LV dysfunction; LV failure; impaired filling; reduced cardiac output; HFpEF; HFrEF; heart failure preserved ejection fraction; heart failure reduced ejection fraction; decompensated heart failure; acute decompensated heart failure; ADHF
Line 35: Line 35:


== Treatment ==
== Treatment ==
=== Treatment of Heart failure with reduced ejection fraction ===
=== Treatment of Heart failure with reduced ejection fraction ===
: '''[[Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction|Pharmacological treatments for patients with heart failure with reduced ejection fraction]]''':
: '''[[Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction|Pharmacological treatments for patients with heart failure with reduced ejection fraction]]''':
====All patients:==== [[Congestive heart failure Angiotensin-converting enzyme inhibitors|Angiotensin-converting enzyme inhibitors]] | [[Congestive heart failure beta blockers|Beta Blockers]] | [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]] | [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]] | [[Congestive heart failure Sodium-glucose co-transporter 2 inhibitors|Sodium-glucose co-transporter 2 inhibitors]]  
*'''In all patients:''' [[Congestive heart failure Angiotensin-converting enzyme inhibitors|Angiotensin-converting enzyme inhibitors]] | [[Congestive heart failure beta blockers|Beta Blockers]] | [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]] | [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]] | [[Congestive heart failure Sodium-glucose co-transporter 2 inhibitors|Sodium-glucose co-transporter 2 inhibitors]]  
====In selected patients:==== [[Congestive heart failure diuretics|Diuretics]] | [[Congestive heart failure angiotensin receptor blockers|Angiotensin receptor blockers]] | [[Congestive heart failure If-channel inhibitor|I<sub>f</sub>-channel inhibitor]] | [[Combination of hydralazine and isosorbide dinitrate]] | [[Congestive heart failure Digoxin|Digoxin]]
*'''In selected patients:''' [[Congestive heart failure diuretics|Diuretics]] | [[Congestive heart failure angiotensin receptor blockers|Angiotensin receptor blockers]] | [[Congestive heart failure If-channel inhibitor|I<sub>f</sub>-channel inhibitor]] | [[Combination of hydralazine and isosorbide dinitrate]] | [[Congestive heart failure Digoxin|Digoxin]] | [[Congestive heart failure iron|Iron]]
 
Guideline-recommended medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) can be suggested by the [https://decisionalgorithm.shinyapps.io/heartfailure/ Heart Failure Educational Decision Aid] medication optimization algorithm<ref name="DorschSifuentesCordwin2023">{{cite journal | last1 = Dorsch | first1 = Michael P. | last2 = Sifuentes | first2 = Aaron | last3 = Cordwin | first3 = David J. | last4 = Kuo | first4 = Rachel | last5 = Rowell | first5 = Brigid E. | last6 = Arzac | first6 = Juan J. | last7 = DeBacker | first7 = Ken | last8 = Guidi | first8 = Jessica L. | last9 = Hummel | first9 = Scott L. | last10 = Koelling | first10 = Todd M. | title = A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction | journal = JACC: Advances | date = April 2023 | page = 100289 | issn = 2772-963X | doi = 10.1016/j.jacadv.2023.100289 | pmid = | url = }}</ref>.
 
: '''Cardiac rhythm management for patients with heart failure with reduced ejection fraction''': [[Congestive heart failure Antiarrhythmic drugs|Antiarrhythmic drugs]] | [[Congestive heart failure Implantable cardioverter defibrillator|Implantable cardioverter defibrillator]] | [[Cardiac resynchronization therapy]]
: '''Cardiac rhythm management for patients with heart failure with reduced ejection fraction''': [[Congestive heart failure Antiarrhythmic drugs|Antiarrhythmic drugs]] | [[Congestive heart failure Implantable cardioverter defibrillator|Implantable cardioverter defibrillator]] | [[Cardiac resynchronization therapy]]
: '''[[Congestive heart failure Nutritional supplements and hormonal therapies|Nutritional supplements and hormonal therapies]]'''
: '''[[Congestive heart failure Nutritional supplements and hormonal therapies|Nutritional supplements and hormonal therapies]]'''
: '''[[Congestive heart failure Exercise training|Exercise training]]'''
: '''[[Congestive heart failure Drugs to avoid|Drugs to avoid]]'''
: '''[[Congestive heart failure Drugs to avoid|Drugs to avoid]]'''
: '''[[Congestive heart failure Drug interactions|Drug interactions]]'''
: '''[[Congestive heart failure Drug interactions|Drug interactions]]'''
Line 50: Line 56:
=== [[Congestive heart failure Management of Acute heart failure | Management of Acute heart failure]] ===
=== [[Congestive heart failure Management of Acute heart failure | Management of Acute heart failure]] ===


===[[Congestive heart failure Management of Advanced heart failure| Management of advanced heart failure]]===
===[[ Management of Advanced heart failure]] ===
[[Congestive heart failure Ultrafiltration|Ultrafiltration]] | [[Congestive heart failure Mechanical circulatory support| Mechanical circulatory support]] | [[Heart transplantation]]
[[Congestive heart failure Ultrafiltration|Ultrafiltration]] | [[Congestive heart failure Mechanical circulatory support| Mechanical circulatory support]] | [[Heart transplantation]]
===Secondary prevention===
Nonpharmacological Interventions:
Education
Social Support
Sodium Restriction: Recommendation
Treatment of Sleep Disorders
Weight Loss
Activity, Exercise Prescription, and Cardiac Rehabilitation
[[Patient education, self-care and lifestyle advice]] | [[Exercise rehabilitation]] | [[Congestive heart failure and exercise|Exercise Training]]
[[Follow-up of chronic heart failure]]
[[Telemonitoring]]


== ACC/AHA Guideline Recommendations ==
== ACC/AHA Guideline Recommendations ==
Line 91: Line 84:


[[Congestive heart failure treatment of special populations|Special Populations]] | [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]] | [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]]
[[Congestive heart failure treatment of special populations|Special Populations]] | [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]] | [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]]
== Sources ==
* [http://circ.ahajournals.org/content/112/12/e154.full.pdf The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult] <ref name="pmid16160202">Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2005) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16160202 ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.] ''Circulation'' 112 (12):e154-235. [http://dx.doi.org/10.1161/CIRCULATIONAHA.105.167586 DOI:10.1161/CIRCULATIONAHA.105.167586] PMID: [http://pubmed.gov/16160202 16160202]</ref>
* [http://content.onlinejacc.org/cgi/reprint/53/15/1343.pdf 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation] <ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]</ref>


==References==
==References==

Latest revision as of 22:20, 19 April 2023



Resident
Survival
Guide
Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure

CDC on Congestive heart failure

Congestive heart failure in the news

Blogs on Congestive heart failure

Directions to Hospitals Treating Congestive heart failure

Risk calculators and risk factors for Congestive heart failure

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2], Mitra Chitsazan, M.D.[3] Seyedmahdi Pahlavani, M.D. [4] Syed Hassan A. Kazmi BSc, MD [5] Edzel Lorraine Co, D.M.D., M.D. [6]

Synonyms and keywords: CHF; pump failure; left heart failure; chronic heart failure; acute heart failure; LV dysfunction; LV failure; impaired filling; reduced cardiac output; HFpEF; HFrEF; heart failure preserved ejection fraction; heart failure reduced ejection fraction; decompensated heart failure; acute decompensated heart failure; ADHF

Overview

Classification

Pathophysiology

Systolic dysfunction | Diastolic dysfunction | HFpEF | HFrEF

Causes

Differentiating Chronic Heart Failure from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | Echocardiography | Cardiac MRI | Exercise Stress Test | Myocardial Viability Studies | Cardiac Catheterization | Invasive hemodynamic monitoring

Treatment

Treatment of Heart failure with reduced ejection fraction

Pharmacological treatments for patients with heart failure with reduced ejection fraction:

Guideline-recommended medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) can be suggested by the Heart Failure Educational Decision Aid medication optimization algorithm[1].

Cardiac rhythm management for patients with heart failure with reduced ejection fraction: Antiarrhythmic drugs | Implantable cardioverter defibrillator | Cardiac resynchronization therapy
Nutritional supplements and hormonal therapies
Exercise training
Drugs to avoid
Drug interactions
Treatment of underlying causes
Treatment of associated conditions

Treatment of Heart failure with preserved ejection fraction

Management of Acute heart failure

Management of Advanced heart failure

Ultrafiltration | Mechanical circulatory support | Heart transplantation

ACC/AHA Guideline Recommendations

Hospitalized Patients

Patients With a Prior MI

Sudden Cardiac Death Prevention

Stage A: Patients at High Risk for Developing Heart Failure

Treatment of Hypertension | Treatment of Diabetes Mellitus | Management of Metabolic Syndrome | Management of Atherosclerotic Disease | Control of Conditions That May Cause Heart Failure | ACC/AHA Guideline Recommendations

Stage B: Patients with Cardiac Structural Abnormalities

Stage C: Patients with Current or Prior Heart Failure Symptoms

Stage D: Patients with Refractory End-stage Heart Failure

Implementation of Practice Guidelines

End-Of-Life Considerations

Specific Groups

Special Populations | Patients who have concomitant disorders | Obstructive Sleep Apnea in the Patient with CHF

References

  1. Dorsch, Michael P.; Sifuentes, Aaron; Cordwin, David J.; Kuo, Rachel; Rowell, Brigid E.; Arzac, Juan J.; DeBacker, Ken; Guidi, Jessica L.; Hummel, Scott L.; Koelling, Todd M. (April 2023). "A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction". JACC: Advances: 100289. doi:10.1016/j.jacadv.2023.100289. ISSN 2772-963X.

Template:WikiDoc Sources